Premium
HAC‐cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating Chemotherapy With Intensification
Author(s) -
Coleman Morton,
Pasmantier Mark W.,
Silver Richard T.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850515)55:10<2342::aid-cncr2820551008>3.0.co;2-2
Subject(s) - medicine , cyclophosphamide , chemotherapy , ovary , regimen , toxicity , ovarian carcinoma , cisplatin , doxorubicin , adenocarcinoma , oncology , surgery , gastroenterology , ovarian cancer , cancer
Twenty‐two previously untreated patients with adenocarcinoma of the ovary were treated with 28 day cycles of hexamethylmelamine, Adriamycin (doxorubicin), and cisplatin (HAC) for 9 months followed by three monthly cycles of intense intravenous cyclophosphamide. An overall response frequency of 82% (18/22) was achieved. Complete pathologic responses (CPR) documented by second look operations were found in 50% (11/22); however, patients considered to be free of disease (prolonged complete clinical response refusing “second look” and CPR) totaled 59%. Median survival has not been reached after a median follow‐up of 34 months. No major or life threatening toxicity was encountered. HAC followed by cyclophosphamide is a highly effective regimen that may be easily administered on an outpatient basis with comparatively little toxicity.